Abstracts tagged "management and rheumatoid arthritis (RA)"

Abstract Number: 610 • 2018 ACR/ARHP Annual Meeting
4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
María Lourdes Ladehesa-Pineda¹, M. Carmen Castro-Villegas¹, Montserrat Romero Gómez¹, Clementina López-Medina², Laura Pérez Sánchez³, Ignacio Gómez-García⁴, Pilar Carreto Font⁵, Alejandro Escudero-Contreras², Eduardo Collantes-Estévez² and Pilar Font-Ugalde², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Rheumatology, Hospital Universitario Reina Sofia, CÓRDOBA, Spain, ⁵Centro de Salud Tudera de Duero. Área Este de Valladolid, Valladolid. SPAIN, Valladolid, Spain
Background/Purpose: Once sustained clinical remission is achieved under tratment with biological therapies, the most efficient strategy is optimization. Searching for the lowest effective dose for…
Abstract Number: 1153 • 2016 ACR/ARHP Annual Meeting
Exploring Perceptions of a Rheumatoid Arthritis Specific Smoking Cessation Programme
Pip Aimer¹, Lisa K. Stamp², Simon Stebbings³, Vicky Cameron¹, Sandra Kirby⁴ and Gareth Treharne⁵, ¹Medicine, University of Otago, Christchurch, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ⁴Arthritis New Zealand, Wellington, New Zealand, ⁵Psychology, University of Otago, Dunedin, New Zealand
Background/Purpose: Premature mortality rates in individuals with rheumatoid arthritis (RA) are significantly higher in current smokers compared to those who have never smoked, making smoking…
Abstract Number: 2082 • 2016 ACR/ARHP Annual Meeting
Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)
Jianlin Huang¹, Hongzhi Wang², Jing Yang³, Wenqiang Fan⁴, Hua Wei⁵, Rong Mu⁶, Xinwang Duan⁷, Xiangyuan Liu⁸, Fang He⁹, Zhenchun Zhang¹⁰, Fei Xiao¹¹, Hui Xiao¹¹, Yuhua Jia¹¹, Yuan Liu¹¹, Li Zhang¹¹, Bing Wu¹¹ and Xiaofeng Li¹², ¹Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ²The First Hospital of Jiaxing, Jiaxing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁷Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁸Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ⁹Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁰People's Hospital of Linyi, Shandong, Linyi, China, ¹¹Gothic Internet Technology Corporation, Shanghai, China, ¹²The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China
Background/Purpose: There are more than 5 million rheumatoid arthritis (RA) patients in China, but only 5,000 rheumatologists. Treat-to-target (T2T) is a widely accepted cretria as…
Abstract Number: 481 • 2015 ACR/ARHP Annual Meeting
Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience
Rok Ješe¹, Aleš Ambrožič¹, Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Martina Plešivčnik Novljan², Sonja Praprotnik¹, Ziga Rotar¹, Alenka Šipek Dolničar¹ and Matija Tomšič¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset is associated with a significant benefit in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].